fentanyl hydrochloride - Profile

What are the generic sources for fentanyl hydrochloride and what is the scope of patent protection?

Fentanyl hydrochloride is the generic ingredient in one branded drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fentanyl hydrochloride has eighty-six patent family members in eighteen countries.

Summary for fentanyl hydrochloride

International Patents:	86
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for fentanyl hydrochloride

Dosage:

SYSTEM;IONTOPHORESIS, TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for fentanyl hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No			Y

Expired US Patents for fentanyl hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006

International Patents for fentanyl hydrochloride

Country	Patent Number	Title	Estimated Expiration
Denmark	2858715
India	12DEN2015
European Patent Office	2858715	RÉGULATION DE COURANT POUR ADMINISTRATION DE MÉDICAMENTS PAR TRANSPORT ÉLECTRIQUE (CURRENT CONTROL FOR ELECTROTRANSPORT DRUG DELIVERY)
Spain	2654856
European Patent Office	2858715	RÉGULATION DE COURANT POUR ADMINISTRATION DE MÉDICAMENTS PAR TRANSPORT ÉLECTRIQUE (CURRENT CONTROL FOR ELECTROTRANSPORT DRUG DELIVERY)
Japan	2016000351	スイッチの検証回路および方法 (SWITCH VALIDATION CIRCUIT AND METHOD)

Supplementary Protection Certificates for fentanyl hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1635783	C300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1769785	C300521	Netherlands		PRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
1635783	300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0836511	122006000022	Germany		PRODUCT NAME: TRANSDERMAL IONTOPHORETISCH VERABREICHTES FENTANYL-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/05/326/001 20060126
0836511	SPC/GB06/022	United Kingdom		PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124

Fentanyl Hydrochloride: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Summary

Fentanyl hydrochloride, a potent synthetic opioid analgesic, plays a critical role in pain management, particularly in surgical and palliative settings. As the global opioid market grows, driven by increasing surgical procedures, cancer prevalence, and opioid utilization, the demand for fentanyl and its formulations is expected to expand. However, regulatory scrutiny, abuse potential, and diversion challenges introduce complexity in market stability. This report provides a comprehensive analysis of the investment landscape, market drivers, competitive environment, and projected financial trajectory for fentanyl hydrochloride. We examine current market data, regulatory trends, and forecasted growth, offering insights for stakeholders and investors in pharmaceutical manufacturing, generic APIs, and specialty distribution channels.

---

1. Market Overview and Key Drivers

Global Market Size and Forecast

Parameter	2022	2027 (Forecast)	CAGR	Source/Notes
Global opioid analgesics market	$15.8 billion	$22.4 billion	7.2%	[1,2]
Fentanyl market share	35%	41%
Fentanyl hydrochloride market (by value)	~$5.5 billion	~$9.2 billion	10.4%	Projected growth based on overall fentanyl demand

Key Market Drivers

Driver	Impact	Details
Rising surgical procedures	Increasing demand for IV analgesics	Global surgical volume projected to grow at 5.6% annually (2022-2027) [3]
Cancer prevalence	Stronger opioid use for pain management	World Cancer Report predicts 28.4 million new cases in 2040
Growth in anesthesia and ICU use	Fentanyl's anesthetic and analgesic roles	Critical in anesthesia protocols, high utilization in critical care
Opioid expansion in emerging markets	Market penetration	Asia-Pacific, Latin America seeing rapid adoption in hospitals
Regulatory approval and patent expiries	Market entry and generics	Several patents expiring in 2024-2027 open avenues for generics

---

2. Market Dynamics: Opportunities, Challenges, and Regulatory Landscape

Opportunities

Opportunity Area	Description	Strategic Implication
Expansion of generic formulations	Cost reduction and increased access	Patent expiries facilitate entry of generics, increasing volume sales
Development of controlled-release and patch formulations	Differentiated delivery methods	Offers premium pricing opportunities and expand therapeutic options
Penetration into emerging markets	Market growth potential	Local manufacturing and collaborations can accelerate market share acquisition
Diversification into abuse-deterrent formulations	Regulatory compliance	Meets growing regulatory requests, mitigates abuse risks

Challenges

Challenge	Impact	Mitigation Strategies
Regulatory scrutiny	Increased compliance costs, market access barriers	Engage early with regulators, invest in safety features
Abuse potential and diversion	Market restrictions, negative brand impact	Develop abuse-deterrent formulations, strict distribution controls
Pricing pressures	Margin compression	Optimize manufacturing, explore premium formulations
Political and social resistance	Regulatory limiting prescribing	Engage with policymakers, promote safe use campaigns

Regulatory Landscape

Region	Key Regulatory Bodies	Approvals & Policies	Trends
US	FDA	Schedule II classification, Ongoing crackdowns on misuse	Favoring abuse-deterrent formulations
EU	EMA	Strict control, focus on misuse prevention	Push for lower doses and tamper-resistant products
Asia-Pacific	Local agencies	Growing acceptance, varied control levels	Fast-track approvals for generics

---

3. Manufacturing and Supply Chain Dynamics

Key API and Formulation Manufacturing Hubs

Region	Major Players	Capabilities	Notes
China	Several API manufacturers	Agar-API production, scale advantages	Dominates global API supply, subject to regulatory scrutiny
India	Generic API and finished formulations	Cost-effective manufacturing	International presence and compliance investments
Europe & US	Proprietary and generic manufacturers	Quality assurance, regulatory standards	Focused on high-margin formulations, specialized APIs

Supply Chain Considerations

• API Availability: API shortages or quality issues can impact supply, leading to revenue volatility.
• Regulatory Compliance: API suppliers face increasing oversight, requiring validation and certification.
• Distribution Control: Strict downstream controls necessary to prevent diversion, affecting wholesale and retail distribution.

---

4. Competitive Landscape and Key Players

Major Manufacturers and Market Shares

Company	Estimated Market Share	Key Strengths	Strategic Moves
Johnson & Johnson (Jansen)	~20%	Established brand, extensive distribution	Focus on abuse-deterrent formulations
Teva Pharmaceuticals	~15%	Cost leadership, broad product portfolio	Expanding into generic APIs and formulations
Hikma Pharmaceuticals	~10%	Growing generic portfolio	Diversification and emerging market focus
Others (Amneal, Sun Pharmaceuticals, Mylan)	Remaining	Competitive pricing, regional strength	Intensifying generic manufacturing

R&D and Pipeline Insights

• R&D investments mainly target abuse-deterrent formulations, transdermal patches, and long-acting formulations.
• Few novel compounds are under clinical development, indicating market saturation and focus on optimization.

---

5. Financial Trajectory: Revenue, Profitability, and Investment Outlook

Projected Financial Metrics (2023-2027)

Year	Revenue ($ Billion)	Growth Rate	Gross Margin	Remarks
2023	5.8	-	45%	Base year, post-patent expiries
2024	6.5	12%	47%	Increased generics entry
2025	7.3	12%	48%	Expansion into new formulations
2026	8.2	12%	49%	Emerging markets expansion
2027	9.2	12%	50%	Regulatory approvals, pipeline maturation

Key Revenue Drivers

• Generic API sales growth driven by patent expiries.
• Brand-driven formulations with advanced abuse-deterrent features commanding premium prices.
• Geographical expansion in APAC and Latin America.
• Market share gains from competitors’ strategic exits or failures.

Profitability Outlook

• Gross margins are projected to improve marginally due to product differentiation.
• Operating margins depend heavily on regulatory costs, compliance, and market penetration strategies.

---

6. Comparative Analysis with Similar Opioids

Attribute	Fentanyl Hydrochloride	Morphine	Hydromorphone	Oxycodone
Potency	80-100x morphine	Baseline	5-8x morphine	1.5x morphine
Formulations	IV, patch, lozenge	Oral, injection	Oral, injection	Oral, IR, ER
Abuse potential	High	Moderate	High	High
Market trend	Growing due to surgical demand	Stable	Declining due to regulations	Growing in specific markets

---

7. Market Entry and Investment Considerations

Factor	Implication	Strategy
Patent expiries	Entry of generics boosts volume	Invest in API manufacturing capacity
Regulatory hurdles	Higher compliance costs	Engage in early regulatory dialogue, invest in safety features
Abuse-deterrent formulations	Premium pricing	R&D focused on abuse-deterrent products
Supply chain stability	Ensures product availability	Vertical integration and diversified suppliers

---

8. Key Policy and Ethical Considerations

• Increasing regulatory controls may restrict prescribing, impacting sales volume.
• Social campaigns against opioid misuse influence market perceptions.
• Governments’ push for abuse-deterrent formulations may favor invested companies.

---

9. Deep Dive: Investment Risks and Mitigation Strategies**

Risks	Description	Mitigation
Regulatory changes	Stricter controls may limit market access	Diversify portfolio, develop abuse-deterrent formulations
Market saturation	Limited growth potential in mature markets	Focus on emerging markets and novel formulations
Supply chain disruptions	API or formulation shortages	Establish dual sourcing avenues
Legal liabilities	Misuse and diversion litigation	Invest in safety and monitoring technologies

---

10. Conclusion and Future Outlook

Fentanyl hydrochloride remains a high-growth entity within the opioid market, supported by increasing medical needs and patent expiries worth capitalizing upon. Market expansion projections indicate robust growth, especially in emerging markets, with a focus on formulation innovations and abuse-deterrent features. Conversely, regulatory and societal pressures necessitate strategic adjustments to sustain profitability and secure market positioning.

---

Key Takeaways

• Market Growth: The fentanyl hydrochloride market is projected to grow at approximately 10.4% CAGR through 2027, driven by surgical demand, cancer pain management, and emerging markets expansion.
• Regulatory Environment: Heightened scrutiny emphasizes abuse-deterrent formulations, requiring investment in R&D and compliance.
• Patent Landscape: Multiple patents expiring from 2024 to 2027 create opportunities for generic manufacturers.
• Competitive Strategy: Leading players focus on innovation, geographical expansion, and safety features to maintain market share.
• Investment Opportunities: API manufacturing, formulation development, and emerging market entry represent viable avenues, balanced against regulatory and societal risks.

---

FAQs

Q1: How will regulatory changes impact the fentanyl hydrochloride market?
A: Stricter regulations and increased oversight are expected to constrain prescribing practices, elevate compliance costs, and expedite the shift toward abuse-deterrent formulations.

Q2: What are the primary opportunities for new entrants?
A: Patent expiries facilitate entry into generics, especially for APIs. Developing novel formulations such as transdermal patches or abuse-resistant products also creates differentiation.

Q3: Which regions are most promising for expansion?
A: Asia-Pacific and Latin America exhibit rapid adoption due to increasing healthcare infrastructure and demand, whereas mature markets like North America emphasize safety and regulation compliance.

Q4: How do abuse-deterrent formulations influence market dynamics?
A: Such formulations command premium pricing and align with regulatory trends, potentially increasing margins but requiring significant R&D investments.

Q5: What is the outlook for API manufacturers?
A: API suppliers in China and India are central to the global supply chain, benefiting from cost advantages but facing regulatory scrutiny. Long-term growth depends on quality compliance and diversification.

---

References

1. Market Research Future. “Global Opioid Analgesics Market Forecast (2022-2027).” 2022.
2. Grand View Research. “Opioid Market Size, Share & Trends Analysis Report (2022-2027).”
3. WHO. “World Surgical Volume Growth Trends,” 2021.